Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020101382 - NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

Publication Number WO/2020/101382
Publication Date 22.05.2020
International Application No. PCT/KR2019/015516
International Filing Date 14.11.2019
IPC
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 405/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
C07D 409/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 417/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
Applicants
  • HK INNO.N CORPORATION [KR]/[KR]
Inventors
  • PARK, Ji-Yeon
  • KIM, Seung Chan
  • KI, So Young
  • SHIM, Ye-Ri
Agents
  • AHN, So Young
Priority Data
10-2018-014057815.11.2018KR
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF
(FR) NOUVEAU COMPOSÉ UTILISÉ EN TANT QU'INHIBITEUR DE PROTÉINE KINASE, ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
Abstract
(EN)
The present invention provides a novel compound having a protein kinase inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof. The compound according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof are effective in preventing or treating protein kinase-related diseases such as cancers, autoimmune diseases, neurological diseases, metabolic diseases, infections or the like by showing a protein kinase inhibitory activity.
(FR)
La présente invention concerne un nouveau composé ayant une activité d'inhibition de protéine kinase, des stéréoisomère ou des sels pharmaceutiquement acceptables de celui-ci. Le composé selon la présente invention, des stéréoisomères ou des sels pharmaceutiquement acceptables de celui-ci sont efficaces dans la prévention ou le traitement de maladies liées à la protéine kinase, telles que des cancers, des maladies auto-immunes, des maladies neurologiques, des maladies métaboliques, des infections ou similaires par la fourniture d'une activité inhibitrice de protéine kinase.
Latest bibliographic data on file with the International Bureau